Compare ENTA & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | BVS |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 617.1M |
| IPO Year | 2012 | 2016 |
| Metric | ENTA | BVS |
|---|---|---|
| Price | $14.47 | $10.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $20.40 | $14.00 |
| AVG Volume (30 Days) | 110.5K | ★ 440.5K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.93 | ★ 163.46 |
| EPS | N/A | ★ 0.33 |
| Revenue | $102,814,000.00 | ★ $568,087,000.00 |
| Revenue This Year | $7.76 | $7.52 |
| Revenue Next Year | N/A | $7.06 |
| P/E Ratio | ★ N/A | $32.03 |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.96 | $5.81 |
| 52 Week High | $17.15 | $10.58 |
| Indicator | ENTA | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 75.26 |
| Support Level | $13.39 | $8.43 |
| Resistance Level | $15.52 | N/A |
| Average True Range (ATR) | 0.75 | 0.36 |
| MACD | 0.21 | 0.15 |
| Stochastic Oscillator | 80.41 | 96.99 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.